Rimonabant, gastrointestinal motility and obesity

Current Neuropharmacology

Volumn 10, Issue 3, 2012, Pages 212-218

  Sun, Yan ^a   Chen, Jiande D Z ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY   (United States)

Author keywords

Food intake; Gastrointestinal motility; Obesity; Rimonabant

Indexed keywords

ENDOCANNABINOID; RIMONABANT;

ARTICLE; BODY SIZE; DEPRESSION; DRUG TOLERABILITY; FOOD INTAKE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRANSIT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OBESITY; STOMACH EMPTYING; SUICIDAL IDEATION; WEIGHT REDUCTION;

EID: 84867536759     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/157015912803217297     Document Type: Article

References (76)

1. www.who.int/health_topic/obesity/en/WHO. 2004, May 6.
2. Hurt, R.T., Frazier, T.H., McClave, S A., Kaplan, L.M. Obesity epidemic: overview, pathophysiology, and the intensive care unit conundrum. JPN J. Parenter Enteral Nutr, 2011, 35,4S-13S.
3. Kordik, C.P., Reitz A.B. Pharmacological treatment of obesity: therapeutic strategies. J. Med. Chem., 1999, 42,181-201.
4. Chapman I., Parker B., Doran S., Feinle-Bisset C., Wishart, J., Lush, C. W., Chen K., Lacerte C., Burns C., McKay R., Weyer C., Horowitz M. Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects. Obesity (Silver Spring)., 2007, 15,1179-86.
5. Sui Y., Zhao HL., Wong VC., Brown N., Li X. L., Kwan A. K., Hui H. L., Ziea E. T., Chan J. C. A systematic review on use of Chinese medicine and acupuncture for treatment of obesity. Obes. Rev., 2012, 13,409-30.
6. Despres, J.P., Golay, A., Sjostrom, L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med., 2005, 353, 2121-34.
7. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J., Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA, 2006, 295,761-75.
8. Van Gaal L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O., Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 2005, 365, 1389-97.
9. De Petrocellis, L., Cascio, M.G., Di Marzo, V. The endocannabinoid system: a general view and latest additions. Br. J. Pharmacol., 2004, 141,765-74.
10. Xing, J., Chen, J.D. Alterations of gastrointestinal motility in obesity. Obes. Res., 2004, 12,1723-32.
11. Janssen, P., Vanden, B. P., Verschueren, S., Lehmann, A., Depoortere, I., Tack, J. Review article: the role of gastric motility in the control of food intake. Aliment Pharmacol. Ther., 2011, 33,880-94.
12. Duggan, J.P., Booth, D.A. Obesity, overeating, and rapid gastric emptying in rats with ventromedial hypothalamic lesions. Science, 1986, 231, 609-11.
13. Andersen, T., Fogh, J. Weight loss and delayed gastric emptying following a South American herbal preparation in overweight patients. J. Hum. Nutr. Diet., 2001, 14,243-50.
14. Tack, J., Caenepeel, P., Fischler, B., Piessevaux, H., Janssens, J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology, 2001, 121,526-35.
15. Park, M.I., Camilleri, M. Gastric motor and sensory functions in obesity. Obes. Res., 2005, 13,491-500.
16. Little, T.J., Horowitz, M., Feinle-Bisset, C. Modulation by high-fat diets of gastrointestinal function and hormones associated with the regulation of energy intake: implications for the pathophysiology of obesity. Am. J. Clin. Nutr., 2007, 86, 531-41.
17. Maljaars, P.W., Peters, H.P., Mela, D.J., Masclee, A.A. Ileal brake: a sensible food target for appetite control. A review. Physiol. Behav., 2008, 95, 271-81.
18. Paradisi, A., Oddi, S., Maccarrone M. The endocannabinoid system in ageing: a new target for drug development. Curr Drug Targets, 2006, 7, 1539-52.
19. Harkany, T., Guzman, M., Galve-Roperh, I., Berghuis, P., Devi, L.A., Mackie, K. The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol. Sci., 2007, 28, 83-92.
20. Kogan, N.M., Mechoulam, R. The chemistry of endocannabinoids. J. Endocrinol. Invest., 2006, 29, 3-14.
21. Fride, E., Bregman, T., Kirkham, T.C. Endocannabinoids and food intake: newborn suckling and appetite regulation in adulthood. Exp. Biol. Med. (Maywood)., 2005, 230, 225-34.
22. Bellocchio, L., Mancini, G., Vicennati, V., Pasquali, R., Pagotto, U. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr. Opin. Pharmacol., 2006, 6, 586-91.
23. Osei-Hyiaman, D., Harvey-White, J., Batkai, S., Kunos, G. The role of the endocannabinoid system in the control of energy homeostasis. Int. J. Obes (Lond)., 2006, 30 Suppl 1,S33-8.
24. Matias, I., Di Marzo, V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab., 2007, 18, 27-37.
25. Howlett, A.C. Cannabinoid receptor signaling. Handb. Exp. Pharmacol., 2005, 53-79.
26. Devane, W.A., Dysarz, F.A., 3rd, Johnson, M.R., Melvin, L.S., Howlett, A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 1988, 34, 605-13.
27. Kulkarni-Narla, A., Brown, D.R. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res., 2000, 302, 73-80.
28. Colombo, G., Agabio, R., Lobina, C., Reali, R., Gessa, G.L. Cannabinoid modulation of intestinal propulsion in mice. Eur. J. Pharmacol., 1998, 344, 67-9.
29. Izzo, A.A., Mascolo, N., Borrelli, F., Capasso, F. Defaecation, intestinal fluid accumulation and motility in rodents: implications of cannabinoid CB1 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol., 1999, 359, 65-70.
30. Croci, T., Manara, L., Aureggi, G., Guagnini, F., Rinaldi-Carmona, M., Maffrand, J.P., Le Fur, G., Mukenge, S., Ferla, G. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. Br. J Pharmacol., 1998, 125,1393-5.
31. Di Carlo G., Izzo, A.A. Cannabinoids for gastrointestinal diseases: potential therapeutic applications. Expert Opin. Investig. Drugs, 2003, 12, 39-49.
32. Vigna, S.R. Cannabinoids and the gut. Gastroenterology, 2003, 125, 973-5.
33. Coutts, A.A., Izzo, A.A. The gastrointestinal pharmacology of cannabinoids: an update. Curr. Opin. Pharmacol., 2004, 4, 572-9.
34. Izzo, A.A., Camilleri, M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut, 2008, 57, 1140-55.
35. Sanger, G.J. Endocannabinoids and the gastrointestinal tract: what are the key questions? Br. J. Pharmacol., 2007, 152, 663-70.
36. Massa, F., Monory, K. Endocannabinoids and the gastrointestinal tract. J. Endocrinol. Invest., 2006, 29, 47-57.
37. Izzo, A.A., Coutts, A.A. Cannabinoids and the digestive tract. Handb. Exp. Pharmacol., 2005, 573-98.
38. Krowicki, Z.K., Moerschbaecher, J.M., Winsauer, P.J., Digavalli, S.V., Hornby, P.J. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur. J. Pharmacol., 1999, 371, 187-96.
39. Sridhar, K., Ricci, D., Large, R., McCallum, R.W. Effects of tetarhydrocannabinol on gastric emptying of solids in humans. Gastroenterology., 1984, 86, 1265.
40. Parker, L.A., Mechoulam, R., Schlievert, C., Abbott, L., Fudge, M.L., Burton, P. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl)., 2003, 166,156-62.
41. Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D., Van Gaal, L.F. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet,2006, 368, 1660-72.
42. Bashashati, M., Storr, MA., Nikas, SP., Wood, J. T., Godlewski, G., Liu, J., Ho, W., Keenan, C. M., Zhang, H., Alapafuja, S. O., Cravatt, B. F., Lutz, B., Mackie, K., Kunos, G., Patel, K. D., Makriyannis, A., Davison, J. S., Sharkey, K. A. Inhibiting fatty acid amide hydrolase normalizes endotoxin-induced enhanced gastrointestinal motility in mice. Br. J. Pharmacol., 2012, 165, 1556-71.
43. Capasso, R., Matias, I., Lutz, B., Borrelli, F., Capasso, F., Marsicano, G., Mascolo, N., Petrosino, S., Monory, K., Valenti, M., Di Marzo, V., Izzo, A. A. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology., 2005, 129, 941-51.
44. Di Marzo, V., Capasso, R., Matias, I., Aviello, G., Petrosino, S., Borrelli, F., Romano, B., Orlando, P., Capasso, F., Izzo, A. A. The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high-fat diet. Br. J. Pharmacol., 2008, 153, 1272-80.
45. Izzo, AA., Fezza, F., Capasso, R., Bisogno, T., Pinto, L., Iuvone, T., Esposito, G., Mascolo, N., Di Marzo, V., Capasso, F. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol., 2001, 134, 563-70.
46. Mascolo, N., Izzo, AA., Ligresti, A., Costagliola, A., Pinto, L., Cascio, M. G., Maffia, P., Cecio, A., Capasso, F., Marzo, V. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J., 2002, 16, 1973-5.
47. Izzo, A.A., Mascolo, N., Capasso, R., Germano, M.P., De Pasquale, R., Capasso, F. Inhibitory effect of cannabinoid agonists on gastric emptying in the rat. Naunyn Schmiedebergs Arch. Pharmacol., 1999, 360, 221-3.
48. Landi, M., Croci, T., Rinaldi-Carmona, M., Maffrand, J.P., Le Fur G., Manara, L. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors. Eur. J. Pharmacol., 2002, 450, 77-83.
49. Ameloot, K., Janssen, P., Scarpellini, E., Vos, R., Boesmans, W., Depoortere, I., Vanden Berghe, P., Tack, J. Endocannabinoid control of gastric sensorimotor function in man. Aliment Pharmacol Ther., 2010, 31, 1123-31.
50. Storr M., Sibaev A., Marsicano G., Lutz B., Schusdziarra V., Timmermans J. P., Allescher H. D. Cannabinoid receptor type 1 modulates excitatory and inhibitory neurotransmission in mouse colon. Am J Physiol Gastrointest Liver Physiol., 2004, 286, G110-7.
51. Hinds, N.M., Ullrich, K., Smid, S.D. Cannabinoid 1 (CB1) receptors coupled to cholinergic motorneurones inhibit neurogenic circular muscle contractility in the human colon. Br. J. Pharmacol., 2006, 148, 191-9.
52. Guagnini, F., Cogliati, P., Mukenge, S., Ferla, G., Croci, T. Tolerance to cannabinoid response on the myenteric plexus of guinea-pig ileum and human small intestinal strips. Br. J. Pharmacol., 2006, 148, 1165-73.
53. Coutts, A.A., Pertwee, R.G. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br. J. Pharmacol., 1997, 121, 1557-66.
54. Izzo, A.A., Mascolo, N., Borrelli, F., Capasso, F. Excitatory transmission to the circular muscle of the guinea-pig ileum: evidence for the involvement of cannabinoid CB1 receptors. Br. J. Pharmacol., 1998, 124, 1363-8.
55. Coutts, A.A., Brewster, N., Ingram, T., Razdan, R.K., Pertwee, R.G. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. Br. J. Pharmacol., 2000, 129, 645-52.
56. Mancinelli, R., Fabrizi, A., Del Monaco, S., Azzena, G. B, Vargiu, R., Colombo, G. C., Gessa, G. L. Inhibition of peristaltic activity by cannabinoids in the isolated distal colon of mouse. Life Sci., 2001, 69, 101-11.
57. Izzo, A.A., Mascolo, N., Pinto, L., Capasso R., Capasso, F. The role of cannabinoid receptors in intestinal motility, defaecation and diarrhoea in rats. Eur. J. Pharmacol., 1999, 384, 37-42.
58. Mule, F., Amato, A., Baldassano, S., Serio, R. Evidence for a modulatory role of cannabinoids on the excitatory NANC neurotransmission in mouse colon. Pharmacol. Res., 2007, 56, 132-9.
59. Makwana, R., Molleman, A., Parsons, M.E. Pharmacological characterization of cannabinoid receptor activity in the rat-isolated ileum myenteric plexus-longitudinal muscle preparation. Br. J. Pharmacol., 2010, 159, 1608-22.
60. Makwana, R., Molleman, A., Parsons, M.E. Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. Br. J. Pharmacol., 2010, 160, 615-26.
61. Arnone, M., Maruani, J., Chaperon, F, Thiebot, M. H., Poncelet, M., Soubrie, P., Le Fur, G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology (Berl)., 1997, 132, 104-6.
62. Freedland, C.S., Poston, J.S., Porrino, L.J. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacol. Biochem. Behav., 2000, 67, 265-70.
63. Colombo, G., Agabio, R., Diaz, G., Lobina, C., Reali, R., Gessa, G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci.,1998, 63, PL113-7.
64. Calignano, A., La Rana, G., Makriyannis, A., Lin, S.Y., Beltramo, M., Piomelli, D. Inhibition of intestinal motility by anandamide, an endogenous cannabinoid. Eur. J. Pharmacol., 1997, 340, R7-8.
65. Ravinet Trillou C., Arnone M., Delgorge C., Gonalons N., Keane P., Maffrand J. P., Soubrie P. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2003, 284, R345-53.
66. Lazzari, P., Sanna, A., Mastinu, A., Cabasino, S., Manca, I., Pani, L. Weight loss induced by rimonabant is associated with an altered leptin expression and hypothalamic leptin signaling in diet-induced obese mice. Behav. Brain Res., 2010, 217, 432-8.
67. Heshmati, H.M., Bellisle, F., Mosse, M., Fauveau, C,. Le Fur, G. SR 141716, a selective cannabinoid CB1 receptor antagonist, reduces hunger, caloric intake, and body weight in overweight or obese men (abstract). Obes. Res., 2001, 9 (suppl 1), S70.
68. No author listed Rimonabant. SR 141716, SR 141716a. Drugs, RD 2002, 3, 65-6.
69. Scheen, A.J., Van Gaal, L.F. [Cardiometabolic effects of rimonabant in obese/overweight subjects with dyslipidaemia or type 2 diabetes]. Rev. Med. Liege., 2007, 62, 81-5.
70. Kelly, D.L., Gorelick, D.A., Conley, R.R., Boggs D.L., Linthicum, J., Liu, F., Feldman, S., Ball, M. P., Wehring, H.J., McMahon, R. P., Huestis, M.A., Heishman, S.J., Warren, K.R., Buchanan, R.W. Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. J. Clin. Psychopharmacol., 2011, 31, 86-91.
71. Carai, M.A., Colombo, G., Gessa, G.L. Rapid tolerance to the intestinal prokinetic effect of cannabinoid CB1 receptor antagonist, SR 141716 (Rimonabant). Eur. J. pharmacol., 2004, 494, 221-4.
72. Van Gaal, L.F., Scheen, A.J., Rissanen, A.M., Rossner, S., Hanotin, C., Ziegler, O. Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. Eur. Heart J., 2008, 29, 1761-71.
73. No author listed Rimonabant: suicide and depression. Depression and suicidal tendencies are about twice as frequent with rimonabant as with placebo. Prescrire Int., 2007, 16 250.
74. No author listed Rimonabant: depression and suicide. Prescrire Int., 2009, 18-24.
75. Buggy, Y., Cornelius, V., Wilton, L., Shakir, S.A. Risk of depressive episodes with rimonabant: a before and after modified prescription event monitoring study conducted in England. Drug Saf., 2011, 34, 501-9.
76. Osei-Hyiaman, D., Liu, J, Zhou, L., Godlewski, G., Harvey-White, J., Jeong, W. I., Batkai, S., Marsicano, G., Lutz, B., Buettner, C., Kunos, G. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J. Clin. Invest., 2008, 118, 3160-9.